Thu, Aug 28, 2014, 11:15 AM EDT - U.S. Markets close in 4 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • modelportfolio2003 modelportfolio2003 Jan 8, 2004 7:30 AM Flag

    MStanley reits outperform on AGN

    Following meeting yesterday with CEO David Pyott, MSt today reits outperform on AGN. Highlights include:
    1. Product portfolio appears robust.
    2. Re Feb 2 R & D meeting: two products will be moving into the clinic in 04--one for GI and one for pain. More details to follow at meeting.
    3. A salesforce of 50-60 reps would be sufficient to cover GI. Pain and urology are two other therapeutic areas that AGN will potentially expand into down the road. Note that emerging uses for Botox include migraine and overactive bladder.
    4. AGN showing great capital discipline with respect to monetizing certain assets thru co-promotion agreements, to concentrate on other products with greater return potential: eg, seeking partners to co-promote oral Taz and Elestat.
    5. Re: competition Botox might face with Ipsen's Dysport. Pyott gave example of Elan's Myobloc as an example of a product that tried to take on Botox in US and failed and says he expects same scenario with Dysport (expected launch 2006).
    6. AGN should begin to realize SG & A leverage over next 2-4 years and get down to industry avg of 37-38%.

    Feb 2 R & D meeting should be very exciting for shareholders to learn more.

    modelportfolio2003

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Following the end of the first quarter of 2005:


      On March 28, 2005, Allergan announced that it entered into an exclusive licensing agreement with Sanwa Kagaku Kenkyusho Co., Ltd. to develop and commercialize Posurdex� for the ophthalmic specialty market in Japan.
      The FDA issued an approvable letter for Alphagan� Z (brimonidine tartrate ophthalmic solution), for the lowering of intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The outstanding approvable issues are primarily related to manufacturing and Allergan anticipates these issues will be resolved in the near future.
      The Medicines and Healthcare products Regulatory Agency granted marketing authorization for Combigan� in the United Kingdom.
      Allergan met with the FDA and reached agreement to enter Phase III clinical trials for Botox� to treat neurogenic overactive bladder and Phase II clinical trials for Botox� to treat idiopathic overactive bladder.



      This was the last information that I have seen concerning the possible use of botox in the bladder.
      Any other news?

 
AGN
162.71-0.05(-0.03%)11:15 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.